PrecisionLife and Ono Pharmaceutical have agreed a multi-target discovery and validation partnership. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyses multi-modal datasets including genomic, clinical, and epidemiological data to accurately stratify patients and […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
